215 related articles for article (PubMed ID: 18711266)
21. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
Kedhar SR; Jabs DA
Herpes; 2007 Dec; 14(3):66-71. PubMed ID: 18371289
[TBL] [Abstract][Full Text] [Related]
22. Incidence Rate and Risk Factors for Contralateral Eye Involvement among Patients with AIDS and Cytomegalovirus Retinitis Treated with Local Therapy.
Sittivarakul W; Benjhawaleemas T; Aui-Aree N; Jirarattanasopa P; Liabsuetrakul T
Ocul Immunol Inflamm; 2016 Oct; 24(5):530-6. PubMed ID: 26327465
[TBL] [Abstract][Full Text] [Related]
23. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis.
Song MK; Azen SP; Buley A; Torriani F; Cheng L; Chaidhawangul S; Ozerdem U; Scholz B; Freeman WR
Am J Ophthalmol; 2003 Oct; 136(4):696-702. PubMed ID: 14516810
[TBL] [Abstract][Full Text] [Related]
24. Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era.
Lai TY; Wong RL; Luk FO; Chow VW; Chan CK; Lam DS
Clin Exp Ophthalmol; 2011 Mar; 39(2):99-104. PubMed ID: 20796263
[TBL] [Abstract][Full Text] [Related]
25. Seven years of HAART impact on ophthalmic management of HIV-infected patients.
Kahraman G; Krepler K; Franz C; Ries E; Maar N; Wedrich A; Rieger A; Dejaco-Ruhswurm I
Ocul Immunol Inflamm; 2005; 13(2-3):213-8. PubMed ID: 16019681
[TBL] [Abstract][Full Text] [Related]
26. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes.
Karavellas MP; Azen SP; MacDonald JC; Shufelt CL; Lowder CY; Plummer DJ; Glasgow B; Torriani FJ; Freeman WR
Retina; 2001; 21(1):1-9. PubMed ID: 11217922
[TBL] [Abstract][Full Text] [Related]
27. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of ocular manifestations and blindness in HIV/AIDS patients on HAART in a tertiary care hospital in western India.
Shah SU; Kerkar SP; Pazare AR
Br J Ophthalmol; 2009 Jan; 93(1):88-90. PubMed ID: 18952644
[TBL] [Abstract][Full Text] [Related]
29. Cystoid macular oedema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy.
Cassoux N; Lumbroso L; Bodaghi B; Zazoun L; Katlama C; LeHoang P
Br J Ophthalmol; 1999 Jan; 83(1):47-9. PubMed ID: 10209434
[TBL] [Abstract][Full Text] [Related]
30. CMV retinitis in the era of HAART.
Cassoux N; Bodaghi B; Katlama C; LeHoang P
Ocul Immunol Inflamm; 1999 Dec; 7(3-4):231-5. PubMed ID: 10611732
[TBL] [Abstract][Full Text] [Related]
31. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy.
Robinson MR; Reed G; Csaky KG; Polis MA; Whitcup SM
Am J Ophthalmol; 2000 Jul; 130(1):49-56. PubMed ID: 11004259
[TBL] [Abstract][Full Text] [Related]
32. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis.
Macdonald JC; Karavellas MP; Torriani FJ; Morse LS; Smith IL; Reed JB; Freeman WR
Ophthalmology; 2000 May; 107(5):877-81; discussion 881-3. PubMed ID: 10811078
[TBL] [Abstract][Full Text] [Related]
33. Ocular manifestations of HIV infection.
Jabs DA
Trans Am Ophthalmol Soc; 1995; 93():623-83. PubMed ID: 8719695
[TBL] [Abstract][Full Text] [Related]
34. [Cytomegalovirus retinitis in pediatric patients with AIDS receiving highly active antiretrovirus therapy].
Dimantas MA; Finamor LP; Ewert V; Nakanami C; Muccioli C
Rev Assoc Med Bras (1992); 2004; 50(3):320-3. PubMed ID: 15499487
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment.
Jabs DA; Van Natta ML; Holbrook JT; Kempen JH; Meinert CL; Davis MD;
Ophthalmology; 2007 Apr; 114(4):780-6. PubMed ID: 17258320
[TBL] [Abstract][Full Text] [Related]
36. Monitoring cytomegalovirus retinitis prevalence in an HIV-seropositive cohort: the assessment of improvements observed following the introduction of highly active antiretroviral triple therapy.
Hutchinson S; Courtney R; Mulcahy F; O'Connor M; Mullaney S; Kilbride R
Int J STD AIDS; 1999 Oct; 10(10):652-6. PubMed ID: 10582631
[TBL] [Abstract][Full Text] [Related]
37. Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis.
Kempen JH; Jabs DA; Wilson LA; Dunn JP; West SK
Am J Ophthalmol; 2005 Jun; 139(6):1028-34. PubMed ID: 15953432
[TBL] [Abstract][Full Text] [Related]
38. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
39. Ophthalmic manifestations of HIV in the highly active anti-retroviral therapy era.
Mowatt L
West Indian Med J; 2013; 62(4):305-12. PubMed ID: 24756590
[TBL] [Abstract][Full Text] [Related]
40. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy.
Holbrook JT; Jabs DA; Weinberg DV; Lewis RA; Davis MD; Friedberg D;
Arch Ophthalmol; 2003 Jan; 121(1):99-107. PubMed ID: 12523893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
